1.51
+23.77%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Inovio Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Inovio Pharmaceuticals is based in Plymouth Meeting, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker INO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $65,343 and a net loss of $84.9m. At that date it held total assets of $74.3m and shareholders' equity of $24.1m.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Dec 1998
- Employees
- 112
- Website
- inovio.com ↗
- Head office
- 660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Simon BenitoIndependent Chairman of the Board$160,466
- Dr. Jacqueline SheaPresident, Chief Executive Officer, Director, since 2019$2.1m
- Mr. Jay ShepardNon-Executive Independent Vice Chairman of the Board$129,841
- Mr. Peter KiesChief Financial Officer$940,072
- Dr. Laurent HumeauChief Scientific Officer$1.1m
- Dr. Michael SumnerChief Medical Officer$1.0m
- Dr. David WeinerDirector$174,341
- Dr. Roger DanseyIndependent Director$117,341
- Dr. Ann MillerIndependent Director$156,641
- Ms. Wendy YarnoIndependent Director$132,341
- Ms. Lota ZothIndependent Director$127,341
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 73
- Environment
- 76
- Social
- 96
- Governance
- 47
- Women in the workforce
- 43%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Inovio Pharmaceuticals has a late-stage biotechnology platform focused on DNA-based immunotherapies.
- The company's CELLECTRA electroporation delivery technology enhances immune responses in the body.
- Inovio's pipeline includes clinical programs for HPV, cancer, and viral diseases like HIV and Ebola.
Weaknesses
- Inovio employs 112 full-time employees, which is fewer than the 190 mentioned in the business description.
- The company has not completed any clinical programs for its SynCon immunotherapies as of the facts provided.
- Inovio's business description states it has 190 employees, but the facts list 112, creating a discrepancy.
Opportunities
- Inovio's SynCon immunotherapies target HPV-caused pre-cancers and cancers with potential market growth.
- The company's CELLECTRA technology can be applied to new viral diseases like influenza and MERS.
- Inovio's pipeline includes clinical programs for hepatitis C and HIV, which have significant global health needs.
Threats
- Inovio's clinical programs for HPV and cancer face competition from existing treatments in the Health Care sector.
- The company's reliance on DNA-based immunotherapies may face regulatory challenges in the Biotechnology industry.
- Inovio's employee count discrepancy could lead to investor concerns about operational stability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.